2 results
Approved WMOPending
The BeyeOMARKER study*s primary aim is to (1) provide proof-of-concept for blood-based biomarkers as a tool for minimally invasive early detection of AD pathology in a diverse population from an alternative clinically relevant setting. Secondly, we…
Approved WMOCompleted
Primary objective:* To evaluate the efficacy of norursodeoxycholic acid (norUDCA) 1500 mg vs. norUDCA 1000 mg vs. placebo for the treatment of NASHSecondary objectiveTo study safety and tolerability (adverse events [AEs], laboratory parameters) of…